1 Report Business Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 1.2.2 Transthyretin Stabilizers 1.2.3 Nonsteroidal Anti-inflammatory Drugs (NSAID) 1.2.4 RNAi Therapy 1.2.5 Others 1.3 Market by Application 1.3.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 1.3.2 Hereditary Transthyretin Amyloidosis (hATTR) 1.3.3 Wild Type Transthyretin Amyloidosis (wtATTR) 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Perspective (2017-2028) 2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Growth Trends by Region 2.2.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Region (2017-2022) 2.2.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Region (2023-2028) 2.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Dynamics 2.3.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Industry Trends 2.3.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Drivers 2.3.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges 2.3.4 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Revenue 3.1.1 Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Revenue (2017-2022) 3.1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Players (2017-2022) 3.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue 3.4 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Ratio 3.4.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2021 3.5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Key Players Head office and Area Served 3.6 Key Players Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Solution and Service 3.7 Date of Enter into Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Breakdown Data by Type 4.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Type (2017-2022) 4.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Type (2023-2028) 5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Breakdown Data by Application 5.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Application (2017-2022) 5.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2017-2028) 6.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type 6.2.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022) 6.2.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028) 6.2.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2017-2028) 6.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application 6.3.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022) 6.3.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028) 6.3.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2017-2028) 6.4 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country 6.4.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2017-2022) 6.4.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2023-2028) 6.4.3 U.S. 6.4.4 Canada 7 Europe 7.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2017-2028) 7.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type 7.2.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022) 7.2.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028) 7.2.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2017-2028) 7.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application 7.3.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022) 7.3.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028) 7.3.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2017-2028) 7.4 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country 7.4.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2017-2022) 7.4.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2023-2028) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2017-2028) 8.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type 8.2.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022) 8.2.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028) 8.2.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2017-2028) 8.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application 8.3.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022) 8.3.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028) 8.3.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2017-2028) 8.4 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region 8.4.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2017-2022) 8.4.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2023-2028) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2017-2028) 9.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type 9.2.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022) 9.2.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028) 9.2.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2017-2028) 9.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application 9.3.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022) 9.3.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028) 9.3.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2017-2028) 9.4 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country 9.4.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2017-2022) 9.4.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2023-2028) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2017-2028) 10.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type 10.2.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022) 10.2.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028) 10.2.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2017-2028) 10.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application 10.3.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022) 10.3.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028) 10.3.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2017-2028) 10.4 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country 10.4.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2017-2022) 10.4.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2023-2028) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Pfizer Inc 11.1.1 Pfizer Inc Company Details 11.1.2 Pfizer Inc Business Overview 11.1.3 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction 11.1.4 Pfizer Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) 11.1.5 Pfizer Inc Recent Developments 11.2 GlaxoSmithKline Plc 11.2.1 GlaxoSmithKline Plc Company Details 11.2.2 GlaxoSmithKline Plc Business Overview 11.2.3 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction 11.2.4 GlaxoSmithKline Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) 11.2.5 GlaxoSmithKline Plc Recent Developments 11.3 Eidos Therapeutics 11.3.1 Eidos Therapeutics Company Details 11.3.2 Eidos Therapeutics Business Overview 11.3.3 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction 11.3.4 Eidos Therapeutics Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) 11.3.5 Eidos Therapeutics Recent Developments 11.4 Ionis Pharmaceuticals, Inc 11.4.1 Ionis Pharmaceuticals, Inc Company Details 11.4.2 Ionis Pharmaceuticals, Inc Business Overview 11.4.3 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction 11.4.4 Ionis Pharmaceuticals, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) 11.4.5 Ionis Pharmaceuticals, Inc Recent Developments 11.5 Alnylam Pharmaceuticals 11.5.1 Alnylam Pharmaceuticals Company Details 11.5.2 Alnylam Pharmaceuticals Business Overview 11.5.3 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction 11.5.4 Alnylam Pharmaceuticals Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) 11.5.5 Alnylam Pharmaceuticals Recent Developments 11.6 Prothena Corporation Plc 11.6.1 Prothena Corporation Plc Company Details 11.6.2 Prothena Corporation Plc Business Overview 11.6.3 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction 11.6.4 Prothena Corporation Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) 11.6.5 Prothena Corporation Plc Recent Developments 11.7 Intellia Therapeutics, Inc 11.7.1 Intellia Therapeutics, Inc Company Details 11.7.2 Intellia Therapeutics, Inc Business Overview 11.7.3 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction 11.7.4 Intellia Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) 11.7.5 Intellia Therapeutics, Inc Recent Developments 11.8 Corino Therapeutics, Inc 11.8.1 Corino Therapeutics, Inc Company Details 11.8.2 Corino Therapeutics, Inc Business Overview 11.8.3 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction 11.8.4 Corino Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) 11.8.5 Corino Therapeutics, Inc Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Author Details 13.3 Disclaimer

List of Tables Table 1. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028 Table 2. Key Players of Transthyretin Stabilizers Table 3. Key Players of Nonsteroidal Anti-inflammatory Drugs (NSAID) Table 4. Key Players of RNAi Therapy Table 5. Key Players of Others Table 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028 Table 7. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 8. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2017-2022) & (US$ Million) Table 9. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Region (2017-2022) Table 10. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 11. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Region (2023-2028) Table 12. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Trends Table 13. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Drivers Table 14. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges Table 15. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Restraints Table 16. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue by Players (2017-2022) & (US$ Million) Table 17. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Share by Players (2017-2022) Table 18. Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment as of 2021) Table 19. Ranking of Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Companies by Revenue (US$ Million) in 2021 Table 20. Global 5 Largest Players Market Share by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (CR5 and HHI) & (2017-2022) Table 21. Key Players Headquarters and Area Served Table 22. Key Players Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Solution and Service Table 23. Date of Enter into Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022) & (US$ Million) Table 26. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2017-2022) Table 27. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 28. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2023-2028) Table 29. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022) & (US$ Million) Table 30. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Share by Application (2017-2022) Table 31. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 32. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Share by Application (2023-2028) Table 33. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022) & (US$ Million) Table 34. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028) & (US$ Million) Table 35. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022) & (US$ Million) Table 36. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028) & (US$ Million) Table 37. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2017-2022) & (US$ Million) Table 38. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2023-2028) & (US$ Million) Table 39. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022) & (US$ Million) Table 40. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028) & (US$ Million) Table 41. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022) & (US$ Million) Table 42. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028) & (US$ Million) Table 43. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2017-2022) & (US$ Million) Table 44. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2023-2028) & (US$ Million) Table 45. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022) & (US$ Million) Table 46. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028) & (US$ Million) Table 47. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022) & (US$ Million) Table 48. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028) & (US$ Million) Table 49. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2017-2022) & (US$ Million) Table 50. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2023-2028) & (US$ Million) Table 51. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022) & (US$ Million) Table 52. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028) & (US$ Million) Table 53. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022) & (US$ Million) Table 54. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028) & (US$ Million) Table 55. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2017-2022) & (US$ Million) Table 56. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2023-2028) & (US$ Million) Table 57. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2017-2022) & (US$ Million) Table 58. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2023-2028) & (US$ Million) Table 59. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2017-2022) & (US$ Million) Table 60. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2023-2028) & (US$ Million) Table 61. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2017-2022) & (US$ Million) Table 62. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2023-2028) & (US$ Million) Table 63. Pfizer Inc Company Details Table 64. Pfizer Inc Business Overview Table 65. Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Table 66. Pfizer Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) & (US$ Million) Table 67. Pfizer Inc Recent Developments Table 68. GlaxoSmithKline Plc Company Details Table 69. GlaxoSmithKline Plc Business Overview Table 70. GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Table 71. GlaxoSmithKline Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) & (US$ Million) Table 72. GlaxoSmithKline Plc Recent Developments Table 73. Eidos Therapeutics Company Details Table 74. Eidos Therapeutics Business Overview Table 75. Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Table 76. Eidos Therapeutics Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) & (US$ Million) Table 77. Eidos Therapeutics Recent Developments Table 78. Ionis Pharmaceuticals, Inc Company Details Table 79. Ionis Pharmaceuticals, Inc Business Overview Table 80. Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Table 81. Ionis Pharmaceuticals, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) & (US$ Million) Table 82. Ionis Pharmaceuticals, Inc Recent Developments Table 83. Alnylam Pharmaceuticals Company Details Table 84. Alnylam Pharmaceuticals Business Overview Table 85. Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Table 86. Alnylam Pharmaceuticals Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) & (US$ Million) Table 87. Alnylam Pharmaceuticals Recent Developments Table 88. Prothena Corporation Plc Company Details Table 89. Prothena Corporation Plc Business Overview Table 90. Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Table 91. Prothena Corporation Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) & (US$ Million) Table 92. Prothena Corporation Plc Recent Developments Table 93. Intellia Therapeutics, Inc Company Details Table 94. Intellia Therapeutics, Inc Business Overview Table 95. Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Table 96. Intellia Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) & (US$ Million) Table 97. Intellia Therapeutics, Inc Recent Developments Table 98. Corino Therapeutics, Inc Company Details Table 99. Corino Therapeutics, Inc Business Overview Table 100. Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Table 101. Corino Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) & (US$ Million) Table 102. Corino Therapeutics, Inc Recent Developments Table 103. Research Programs/Design for This Report Table 104. Key Data Information from Secondary Sources Table 105. Key Data Information from Primary Sources List of Figures Figure 1. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type: 2021 VS 2028 Figure 2. Transthyretin Stabilizers Features Figure 3. Nonsteroidal Anti-inflammatory Drugs (NSAID) Features Figure 4. RNAi Therapy Features Figure 5. Others Features Figure 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application: 2021 VS 2028 Figure 7. Hereditary Transthyretin Amyloidosis (hATTR) Case Studies Figure 8. Wild Type Transthyretin Amyloidosis (wtATTR) Case Studies Figure 9. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Report Years Considered Figure 10. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 11. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 12. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Region: 2021 VS 2028 Figure 13. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Players in 2021 Figure 14. Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment as of 2021) Figure 15. The Top 10 and 5 Players Market Share by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2021 Figure 16. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY (2017-2028) & (US$ Million) Figure 17. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Type (2017-2028) Figure 18. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Application (2017-2028) Figure 19. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Share by Country (2017-2028) Figure 20. United States Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 21. Canada Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 22. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY (2017-2028) & (US$ Million) Figure 23. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Type (2017-2028) Figure 24. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Application (2017-2028) Figure 25. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Share by Country (2017-2028) Figure 26. Germany Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. France Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. U.K. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. Italy Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Russia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Nordic Countries Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY (2017-2028) & (US$ Million) Figure 33. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Type (2017-2028) Figure 34. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Application (2017-2028) Figure 35. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Share by Region (2017-2028) Figure 36. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 40. India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. Australia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million) List of Figures Figure 42. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY (2017-2028) & (US$ Million) Figure 43. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Type (2017-2028) Figure 44. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Application (2017-2028) Figure 45. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Share by Country (2017-2028) Figure 46. Mexico Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 47. Brazil Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 48. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY (2017-2028) & (US$ Million) Figure 49. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Type (2017-2028) Figure 50. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Application (2017-2028) Figure 51. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Share by Country (2017-2028) Figure 52. Turkey Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 53. Saudi Arabia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 54. UAE Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 55. Pfizer Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) Figure 56. GlaxoSmithKline Plc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) Figure 57. Eidos Therapeutics Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) Figure 58. Ionis Pharmaceuticals, Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) Figure 59. Alnylam Pharmaceuticals Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) Figure 60. Prothena Corporation Plc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) Figure 61. Intellia Therapeutics, Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) Figure 62. Corino Therapeutics, Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2017-2022) Figure 63. Bottom-up and Top-down Approaches for This Report Figure 64. Data Triangulation Figure 65. Key Executives Interviewed

Pfizer Inc GlaxoSmithKline Plc Eidos Therapeutics Ionis Pharmaceuticals, Inc Alnylam Pharmaceuticals Prothena Corporation Plc Intellia Therapeutics, Inc Corino Therapeutics, Inc